At a glance
ClinicalIndex Comparison RecordN/ACompleted· 78 enrolled
Drug / intervention
Probiotic +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effectiveness of Weizmannia Coagulans BC99 in Alleviating Allergic Rhinitis in Adults and Its Impact on the Gut Microbiota.
In Brief
A clinical study evaluating Probiotic and Maltodextrin for Allergic Rhinitis. Completed, enrolled 78 participants across 1 site.
Detailed Summary
Assessing the clinical efficacy of weizmannia coagulans BC99 in alleviating allergic rhinitis symptoms, improving gut microbiota, and reducing adverse reactions in patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20252026
First PostedNov 2024
Enrollment StartNov 2024
Primary CompletionDec 2024
Study CompletionMar 2025
TodayJul 2026
First PostedNov 8, 2024
Enrollment StartNov 25, 2024
Primary CompletionDec 25, 2024
Study CompletionMar 25, 2025
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 1.7 years ago
Interventions
Probioticdietary
The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.
Maltodextrindietary
The experimental phase of this study lasts for 8 weeks, with each patient making three visits at weeks 1, 4, and 8.